Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of presynaptic neuromuscular transmission caused by antibodies against voltage-gated calcium channels (VGCCs). First described in the 1950s by Lambert, Eaton, and Rooke, LEMS is characterized by the clinical triad of proximal muscle weakness, autonomic dysfunction, and hyporeflexia with post-exercise facilitation. Approximately 50–60% of cases are paraneoplastic, most commonly associated with small cell lung carcinoma (SCLC), while the remainder are classified as autoimmune (nontumor) LEMS. Early recognition is critical because LEMS may be the first manifestation of an occult malignancy, and effective treatments — particularly 3,4-diaminopyridine (amifampridine) — can substantially improve neuromuscular function.
Bottom Line
- Mechanism: Autoantibodies against presynaptic P/Q-type VGCCs reduce calcium influx and acetylcholine (ACh) release at the neuromuscular junction
- Clinical triad: Fatigable proximal weakness (legs > arms), autonomic dysfunction (dry mouth, constipation, erectile dysfunction), and hyporeflexia/areflexia with post-exercise facilitation
- Paraneoplastic association: 50–60% have underlying SCLC; the DELTA-P score and SOX1 antibodies help stratify cancer risk at presentation
- Electrodiagnostics: Low baseline CMAPs, decrement at 2–3 Hz RNS, and ≥60–100% increment after brief exercise or high-frequency stimulation — the hallmark of a presynaptic NMJ disorder
- First-line treatment: Amifampridine (3,4-diaminopyridine / Firdapse); FDA-approved for LEMS in adults and pediatric patients ≥6 years
- Cancer screening: CT chest at diagnosis; if negative, repeat imaging every 3–6 months for at least 2 years; FDG-PET if CT is unrevealing
- Prognosis: Nontumor LEMS has near-normal survival; SCLC-LEMS prognosis is driven by the malignancy, but tumor treatment often improves neuromuscular symptoms
Pathophysiology
LEMS is a presynaptic disorder of neuromuscular transmission. The pathogenic antibodies, found in approximately 85–90% of LEMS patients, target P/Q-type VGCCs located on the presynaptic motor nerve terminal. Under normal conditions, the arrival of a nerve action potential opens VGCCs, allowing calcium influx that triggers synaptic vesicle docking and ACh release into the synaptic cleft.
In LEMS, antibody binding to VGCCs causes cross-linking and internalization (antigenic modulation) of the channels, reducing the density of functional VGCCs at active zones. This leads to decreased calcium entry per nerve impulse and consequently reduced quantal ACh release. The end result is a subthreshold endplate potential that fails to generate a muscle fiber action potential — producing clinical weakness.
Paraneoplastic vs. Autoimmune LEMS
- SCLC-LEMS (~50–60%): P/Q-type VGCCs are expressed on the surface of SCLC tumor cells. The antitumor immune response generates antibodies that cross-react with neuronal VGCCs at the NMJ. Males predominate, and most patients are smokers. Immune checkpoint inhibitor therapy for SCLC has also been reported to trigger or unmask LEMS.
- Nontumor LEMS (~40–50%): Driven by a primary autoimmune process. There is a genetic predisposition involving HLA-B8 and HLA-DR3 associations, and patients have an increased prevalence of other autoimmune conditions (thyroid disease, type 1 diabetes, vitiligo). A bimodal age distribution is observed — a first peak around age 35 (female predominance) and a second peak around age 60.
Clinical Features
The Classic Triad
| Feature | Details |
|---|---|
| Proximal weakness | Usually begins in the lower limbs (difficulty rising from a chair, climbing stairs); upper limb weakness follows. Fatigable and worsens with sustained activity. Oculobulbar symptoms (ptosis, diplopia, dysphagia, dysarthria) occur later and are typically milder than in MG. Respiratory failure is uncommon but can occur. |
| Autonomic dysfunction | Present in the majority of patients; may be the earliest symptom. Dry mouth is the most common complaint. Other features include constipation, erectile dysfunction, orthostatic hypotension, and impaired sweating. Must be specifically elicited on history. |
| Hyporeflexia/areflexia | Decreased or absent muscle stretch reflexes at rest. Post-exercise facilitation: After brief maximal contraction (10–15 seconds), reflexes may transiently return and strength temporarily improves. This is a pathognomonic bedside finding of presynaptic NMJ disorders. |
Post-Exercise Facilitation: The Bedside Test
- Ask the patient to rest for several minutes, then check muscle stretch reflexes (typically absent or diminished)
- Instruct the patient to contract the target muscle maximally for 10–15 seconds (e.g., quadriceps contraction before checking knee jerk)
- Immediately retest the reflex — a previously absent reflex that now appears (or markedly increases) is post-exercise facilitation
- This phenomenon also applies to muscle strength: grip or proximal power may transiently improve after brief maximal effort, then fatigue with sustained activity
- The effect is transient (fades within 30–60 seconds) because calcium accumulation in the nerve terminal dissipates quickly
Disease Progression
SCLC-LEMS progresses faster than nontumor LEMS. Weakness follows an ascending pattern: proximal lower limbs → proximal upper limbs → oculobulbar muscles. Unlike MG, isolated ocular onset is essentially absent in LEMS (95% present with limb weakness as the first symptom). Respiratory involvement, when it occurs, tends to be less frequent and less severe than in MG.
Cancer Screening and Risk Stratification
Cancer Screening is Mandatory in All LEMS Patients
- An associated tumor (most commonly SCLC) is found in 50–60% of LEMS patients; in most cases, the cancer is undiagnosed at the time of LEMS presentation
- 96% of SCLC-LEMS cancers are identified within 1 year of LEMS diagnosis
- Initial workup: CT chest (with contrast) at diagnosis — CT detects ~93% of tumors (far superior to chest X-ray at 51%)
- If CT negative: FDG-PET/CT should be performed
- Ongoing surveillance: Repeat imaging every 3–6 months for a minimum of 2 years
- High-risk patients (DELTA-P ≥3 or positive SOX1 antibodies): screen every 3 months
- Whole-body CT and FDG-PET are the recommended screening modalities
DELTA-P Score
The Dutch-English LEMS Tumour Association Prediction (DELTA-P) score is a validated clinical tool that predicts the likelihood of underlying SCLC at the time of LEMS diagnosis. Each criterion present at diagnosis (or within 3 months) scores 1 point:
| Criterion | Points |
|---|---|
| Age at symptom onset ≥50 years | 1 |
| Weight loss >5% at presentation | 1 |
| Current smoking at time of diagnosis | 1 |
| Bulbar involvement (dysphagia, dysarthria) | 1 |
| Erectile dysfunction (in males) | 1 |
| Karnofsky performance status <70 | 1 |
Interpretation: Score 0 = 0% SCLC risk; Score 1 = ~19%; Score 2 = ~45%; Score ≥3 = >55% (rising to 100% at score 6). The DELTA-P score achieved an AUC of 94.4–94.6% in derivation and validation cohorts. A score of 0–1 is associated with nontumor LEMS, while a score ≥3 warrants urgent and intensified cancer screening.
SOX1 Antibodies
SOX1 is a transcription factor expressed by SCLC cells and neural tissue. Anti-SOX1 antibodies are a valuable biomarker for identifying paraneoplastic LEMS:
- Present in ~64–67% of SCLC-LEMS patients
- Absent in nontumor LEMS (0% in one large series)
- Sensitivity ~67%, specificity ~95% for discriminating SCLC-LEMS from nontumor LEMS
- SOX1-positive LEMS patients without initial evidence of malignancy should undergo more frequent and prolonged cancer screening
Electrodiagnostic Findings
Electrodiagnostic studies are essential for confirming LEMS and distinguishing it from MG and other NMJ disorders. The classic LEMS triad on nerve conduction studies is: (1) diffusely low CMAP amplitudes, (2) decremental response at low-frequency RNS, and (3) marked facilitation after brief exercise or high-frequency RNS.
Electrodiagnostic Criteria for LEMS
- Baseline CMAPs: Low amplitude (<50% of lower limit of normal) in multiple nerves — diffuse, not restricted to clinically weak muscles; this reflects reduced quantal ACh release at rest
- Low-frequency RNS (2–3 Hz): Decremental response ≥10% (similar to MG, but starting from a low baseline CMAP)
- Post-exercise facilitation (the diagnostic hallmark): After 10–15 seconds of maximal voluntary contraction, CMAP amplitude increases by ≥60–100%; increments of >100% (often 200–400%) are highly characteristic and essentially diagnostic
- High-frequency RNS (30–50 Hz): Produces similar increment but is rarely performed due to pain; the post-exercise facilitation protocol has replaced it in clinical practice
- SFEMG: Shows increased jitter and blocking (>95% sensitivity) but does not distinguish LEMS from MG; useful when RNS is equivocal
- Needle EMG: May show small, short-duration motor unit potentials; fibrillation potentials are generally absent (unlike botulism)
- RNS sensitivity for LEMS: ~100% when all three criteria are assessed (low CMAP + decrement + post-exercise facilitation)
RNS Decrement Pattern: LEMS vs. MG
The decrement pattern on low-frequency RNS differs between LEMS and MG. In MG, the CMAP amplitude reaches its nadir at the 4th–5th stimulus then partially repairs (U-shaped pattern). In LEMS, the CMAP amplitude decreases progressively through the stimulus train without significant repair. The median minimum response occurs at the 8th stimulus in LEMS versus the 5th in MG. The decrement magnitude is also greater in LEMS (median ~37%) compared to MG (median ~21%).
Differentiation from Myasthenia Gravis
| Feature | Lambert-Eaton Myasthenic Syndrome | Myasthenia Gravis |
|---|---|---|
| Site of pathology | Presynaptic (VGCCs) | Postsynaptic (AChR, MuSK, LRP4) |
| Antibody target | P/Q-type VGCC (85–90%) | AChR (85%), MuSK (6–8%), LRP4 (2–5%) |
| Initial presentation | Proximal leg weakness (95%) | Ocular symptoms (60%), bulbar (29%), limb (12%) |
| Ocular involvement | Late and mild; isolated ocular onset is virtually absent | Common; 50–60% present with ptosis/diplopia |
| Weakness distribution | Legs > arms; proximal > distal | Variable; ocular, bulbar, or proximal limb |
| Reflexes | Decreased/absent with post-exercise facilitation | Normal or preserved |
| Autonomic symptoms | Prominent (dry mouth, constipation, erectile dysfunction) | Absent |
| Baseline CMAP | Low amplitude (<50% of normal) | Normal amplitude |
| Low-rate RNS (2–3 Hz) | Decrement present (from low baseline) | Decrement present (from normal baseline) |
| Post-exercise facilitation | ≥60–100% increment (often >200%) | Transient repair of decrement (no significant increment in amplitude) |
| Cancer association | 50–60% (SCLC) | 10–15% (thymoma) |
| Response to AChE inhibitors | Minimal or no improvement | Usually significant improvement |
| First-line symptomatic Rx | Amifampridine (3,4-DAP) | Pyridostigmine |
Diagnostic Criteria
The diagnosis of LEMS is established when the following are present:
- Clinical features of fatigable proximal lower limb weakness with reduced muscle stretch reflexes and autonomic features
- Plus at least one of the following:
- Presence of P/Q-type VGCC antibodies (positive in 85–90%)
- Repetitive nerve stimulation abnormalities: low-amplitude CMAPs, decrement >10% at 1–5 Hz, and increment >60% after maximum voluntary contraction or at high-frequency (50 Hz) stimulation
It is important to note that 5–8% of patients with SCLC have positive VGCC antibodies without clinical LEMS symptoms. Conversely, 10–15% of clinically definite LEMS patients are VGCC-seronegative.
Treatment
LEMS treatment is divided into two parallel strategies: symptomatic management of the myasthenic syndrome and treatment of any underlying malignancy.
Symptomatic Treatment
| Agent | Mechanism | Key Details |
|---|---|---|
| Amifampridine (3,4-DAP) | Blocks presynaptic voltage-gated potassium channels, prolonging the nerve terminal action potential and increasing calcium influx through remaining VGCCs → enhanced ACh release | First-line treatment. FDA-approved as Firdapse for adults and pediatric patients ≥6 years. Starting dose 15–30 mg/day in 3–4 divided doses; titrate up to 60–80 mg/day (maximum 100 mg/day for patients >45 kg per 2024 FDA label expansion). Also proposed to potentiate NMJ transmission via direct action on the VGCC β subunit. |
| Pyridostigmine | Acetylcholinesterase inhibitor; prolongs ACh action in the synaptic cleft | Typically provides minimal benefit as monotherapy in LEMS (unlike MG). May offer modest additional benefit when combined with amifampridine. |
| IVIg | Immunomodulatory | Effective as acute rescue therapy. Used for exacerbations or as bridge therapy while initiating chronic immunosuppression. |
| Plasma exchange (PLEX) | Removes circulating pathogenic antibodies | Effective as acute rescue therapy. Rapid onset but short-lived benefit (2–6 weeks). |
| Prednisone/prednisolone | Broad immunosuppression | Used for patients with persistent moderate–severe symptoms despite amifampridine. Often combined with a steroid-sparing agent. |
| Azathioprine | Purine synthesis inhibitor | Common steroid-sparing agent; onset of action 3–6 months. Often used in combination with prednisone. |
| Rituximab | Anti-CD20 B-cell depletion | Reported beneficial in refractory cases. Emerging data support its use in nontumor LEMS. |
Amifampridine: Practical Prescribing Points
- Most common side effects: perioral and distal paresthesia, mild gastrointestinal disturbance
- Seizures are a rare side effect at doses >100 mg/day but are uncommon at standard therapeutic doses
- Cardiac arrhythmias are rare; ECG monitoring is recommended at initiation
- In May 2024, the FDA approved an expanded maximum daily dose of 80–100 mg for patients weighing >45 kg
- Amifampridine is the only FDA-approved medication specifically indicated for LEMS
- Randomized controlled trials demonstrate significant improvement in quantitative myasthenia gravis (QMG) scores and timed functional measures compared to placebo
Treatment of Underlying Malignancy
In SCLC-LEMS, treatment of the underlying cancer (chemotherapy, radiation, surgery, and/or immunotherapy) is paramount. Successful tumor treatment can produce sustained neuromuscular improvement and, in some cases, eliminate LEMS symptoms entirely. The severity of LEMS should not limit tumor treatment options — oncologic management takes priority.
- Chemotherapy (cisplatin/etoposide regimens) is the standard first-line treatment for SCLC
- Immune checkpoint inhibitors (e.g., atezolizumab, durvalumab) are increasingly used in combination with chemotherapy for extensive-stage SCLC, although they can occasionally trigger or exacerbate LEMS
- Monitor closely for neuromuscular worsening during ICI therapy
Stepwise Treatment Approach
- All patients: Amifampridine as first-line symptomatic therapy
- Inadequate response: Add pyridostigmine (modest additional benefit in some patients)
- Moderate–severe persistent symptoms: Initiate immunosuppression (prednisone ± azathioprine)
- Acute exacerbation or crisis: IVIg or plasma exchange
- Refractory disease: Consider rituximab or other immunosuppressants (mycophenolate, cyclosporine)
- Paraneoplastic LEMS: Treat underlying malignancy as the highest priority alongside symptomatic and immunosuppressive management
Medications That May Worsen LEMS
- Drugs known to impair neuromuscular transmission should be used with extreme caution in LEMS patients
- Aminoglycosides (gentamicin, tobramycin) — inhibit presynaptic calcium channels and reduce ACh release
- Magnesium — competes with calcium at VGCCs; avoid IV magnesium unless absolutely indicated
- Calcium channel blockers — can exacerbate presynaptic calcium channel dysfunction
- Neuromuscular blocking agents — exaggerated and prolonged paralysis; use cautiously if anesthesia is required
- Clindamycin, tetracyclines, fluoroquinolones — theoretical impairment of NMJ transmission
- Patients should carry a medical alert card listing medications to avoid
Prognosis
- Nontumor LEMS: Good long-term prognosis with survival rates comparable to the general population. Symptoms can be well-controlled with amifampridine and immunosuppression. Patients tend to have a stable course after treatment initiation, although exacerbations may occur with intercurrent illness.
- SCLC-LEMS: Prognosis is largely determined by the underlying malignancy. Paradoxically, SCLC-LEMS patients may have better cancer outcomes than SCLC patients without LEMS, likely due to the effective antitumor immune response. Functional impairment is generally greater than in nontumor LEMS, but most patients improve with treatment of both LEMS and the malignancy.
- Immune checkpoint inhibitor-associated LEMS: Cases presenting months after ICI initiation for SCLC have been reported; management requires balancing oncologic and neurologic priorities.
Pediatric LEMS
LEMS in the pediatric population is rare. Clinical symptoms, signs, and neurophysiologic findings are similar to those in adults, although autonomic dysfunction and cancer association are less common. Management follows the same principles as adult LEMS. Amifampridine is FDA-approved for pediatric patients aged 6–17 years.
References
- Ramdas S. Botulism, Lambert-Eaton myasthenic syndrome, and congenital myasthenic syndromes. Continuum (Minneap Minn). 2025;31(5, Muscle and Neuromuscular Junction Disorders).
- Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–1107.
- Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902–908.
- Maddison P, Lipka AF, Gozzard P, et al. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Sci Rep. 2020;10(1):10546.
- Titulaer MJ, Verschuuren JJ, Wirtz PW, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276–4281.
- Sabater L, Titulaer MJ, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924–928.
- Lipka AF, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome. Handb Clin Neurol. 2024;200:307–325.
- Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44–48.
- Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511–e520.
- Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671–673.
- Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467–1474.
- Oh SJ, Hatanaka Y, Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2007;35(2):178–183.